金奧博(002917.SZ):正在研發的機器人關節模組相關產品將應用於工業機器人方面
格隆匯7月24日丨有投資者向金奧博(002917.SZ)提問,“數據顯示特斯拉人形機器人全身共有28個身體關節執行器(14個旋轉關節,14個線性關節)12個手指關節執行器,公司2023-7-6在平台上回復有多關節機器人,正在研發機器人用的關節模組相關產品。請問這個機器人關節模組以後能不能用在人形機器人上?”
金奧博回覆稱,公司在機器人制造方面,主要專注於六軸、並聯和柔性協作工業機器人的本體、運動控制、視覺及其應用的研發與創新,公司正在研發的機器人關節模組相關產品將應用於工業機器人方面。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.